Robeco Institutional Asset Management B.V. Grows Stock Holdings in Medtronic PLC $MDT

Robeco Institutional Asset Management B.V. grew its stake in Medtronic PLC (NYSE:MDT) by 121.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,057 shares of the medical technology company’s stock after acquiring an additional 163,624 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Medtronic were worth $28,387,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of MDT. Norges Bank bought a new position in Medtronic in the second quarter worth approximately $1,432,698,000. Vanguard Group Inc. lifted its holdings in shares of Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after buying an additional 1,895,165 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Medtronic by 332.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock worth $130,300,000 after buying an additional 1,148,803 shares in the last quarter. Perkins Coie Trust Co increased its stake in shares of Medtronic by 2,952.2% during the second quarter. Perkins Coie Trust Co now owns 1,155,425 shares of the medical technology company’s stock valued at $100,718,000 after buying an additional 1,117,570 shares during the period. Finally, Laurel Wealth Advisors LLC raised its holdings in shares of Medtronic by 8,779.8% in the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after acquiring an additional 1,057,618 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Price Performance

NYSE MDT opened at $99.76 on Thursday. The firm’s fifty day simple moving average is $98.02 and its two-hundred day simple moving average is $94.34. The firm has a market capitalization of $127.89 billion, a P/E ratio of 26.89, a P/E/G ratio of 2.64 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the firm earned $1.26 EPS. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Sanford C. Bernstein set a $111.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. Wells Fargo & Company lifted their price objective on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Morgan Stanley upped their target price on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Finally, Stifel Nicolaus increased their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).